Henry Meds vs Reflexmd: Biomarker-Guided Selection and Clinical Readiness

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Henry Meds and Reflexmd are both telemedicine platforms offering GLP-1 prescription services, but they operate under different clinical frameworks, cost models, and eligibility requirements. Choosing between them requires understanding how each platform evaluates your candidacy and what clinical data informs their prescribing decisions.

Full head-to-head: PlexusDx vs Henry Meds →

Beyond price and convenience, the most important factor is whether a platform's clinical approach aligns with your health profile. This includes your baseline metabolic markers, cardiovascular risk factors, and genetic predispositions in peptide signaling pathways. Understanding these elements supports more informed conversations with healthcare providers about which option serves your long-term wellness goals.

How Henry Meds and Reflexmd Structure Clinical Eligibility

Henry Meds requires a BMI of at least 27 with a comorbid condition, or BMI 30 or higher regardless of comorbidities. Reflexmd uses similar BMI thresholds but may have more flexible evaluation for metabolic conditions like prediabetes or polycystic ovary syndrome. Both platforms conduct physician-led consultations, though the depth of metabolic assessment varies.

Neither platform routinely orders comprehensive metabolic panels or genetic peptide pathway screening before prescribing. This means your provider may have limited biomarker context when making initial dosing and medication-choice decisions. Understanding your own metabolic baseline—fasting glucose, insulin levels, lipid profile, and inflammatory markers—helps you engage more meaningfully with either provider during consultation.

Cost, Prescription Model, and Long-Term Affordability Comparison

Henry Meds and Reflexmd differ in how they structure monthly fees, medication costs, and follow-up consultations. This table outlines key financial and operational differences that affect total cost of care and treatment continuity.

Factor	Henry Meds	Reflexmd	Considerations for Your Decision
Initial Consultation	$0 — provider evaluation is free, and nothing is charged until a prescription is written; the all-inclusive subscription runs $297/mo month-to-month for injectable compounded semaglutide	Typically $100–$200, per aggregated listings — verify on Reflexmd’s site	Henry’s evaluation is free; Reflexmd’s fee structure varies — confirm before booking.
Medication Sourcing	Licensed compounding pharmacies; compounded only — tirzepatide as an oral dissolving tablet (as of July 2026)	Licensed compounding pharmacies; sourcing varies by state	Verify that your state permits and your insurance covers the pharmacy model offered.
Ongoing Follow-up	Ongoing care included in the subscription price	Varies; some tiers include follow-ups	Long-term affordability depends on consultation frequency. Ask upfront about annual total costs.
Insurance Coverage	Limited; most users self-pay or use FSA/HSA	Limited; self-pay model typical	GLP-1 for weight loss rarely covered by insurance. Budget accordingly for 6–12 months minimum.

Medication Selection: Semaglutide, Tirzepatide, and Dual-Agonist Compounds

Both platforms can prescribe semaglutide and tirzepatide through licensed compounding pharmacies. At Henry Meds, semaglutide is available as a weekly injection ($297/month month-to-month) or sublingual tablet ($249/month), while tirzepatide is an oral dissolving tablet only (3-month supply, $1,047, or $891 paid in full), as of July 2026 — Henry does not offer injectable or branded tirzepatide. Reflexmd focuses primarily on compounded formulations. The choice between weekly injection and oral dosing also affects both cost and adherence patterns over time.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR and FTO — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to GLP-1 medications or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Who Should Choose Each Platform—And When Provider-Led Biomarker Assessment Matters

Henry Meds may suit patients with straightforward BMI-based eligibility, existing metabolic diagnoses (diabetes, prediabetes), and comfort with a larger platform infrastructure. Reflexmd appeals to those seeking lower-cost consultations and faster prescription turnaround. However, neither platform is ideal if you have complex medical history, polypharmacy concerns, or previous poor tolerance to GLP-1 drugs.

Patients with a personal or family history of medullary thyroid cancer, pancreatitis, or gastroparesis should work with a provider who reviews detailed clinical history and baseline labs before starting therapy. Similarly, if you've experienced poor tolerability with one GLP-1 medication, genetic and biomarker context can inform whether a different compound class might work better. This level of clinical depth is not standard on either platform, making a hybrid approach—platform prescription plus genetic testing and biomarker review—increasingly valuable.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that comparing platforms like Henry Meds and Reflexmd requires more than pricing—it requires understanding your individual biomarker and genetic context. Our Precision Peptide Genetic Test may help provide context about your predispositions in key peptide signaling pathways, including GIPR, FTO, and MC4R variants. This information should be interpreted with a qualified healthcare provider to inform both platform selection and medication choice.

The Precision Peptide Genetic Test ($298) reveals predispositions in peptide genetic pathways that influence how your body responds to GLP-1 and GIP-based therapies. Key variants such as GIPR rs1800437 may help explain why some patients achieve robust weight loss and metabolic improvements while others experience slower responses or higher side effect burden. This test does not predict exact medication response but provides clinically relevant context that supports more personalized treatment planning.

Whether you choose Henry Meds, Reflexmd, or another platform, layering biomarker and genetic assessment into your decision-making process can support a more informed conversation with your provider. Understanding your FTO rs9939609 and MC4R rs17782313 variants, combined with baseline metabolic labs, helps you and your healthcare team set realistic expectations and adjust therapy with greater precision. This data-driven approach moves beyond one-size-fits-all prescribing toward treatment aligned with your unique physiology.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose GLP-1 Protocol is $129/mo flat. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Henry Meds and Reflexmd eligibility?

Henry Meds requires BMI 27+ with comorbidity or BMI 30+ alone; Reflexmd uses similar thresholds but may evaluate metabolic conditions more flexibly. Both require physician consultation. Exact requirements vary by state and individual health profile.

Are compounded medications from either platform FDA-approved?

Compounded semaglutide and tirzepatide are not FDA-approved as branded drugs. They are prepared by licensed 503A pharmacies under physician prescription. Quality and sterility standards vary; verify your pharmacy's licensing and state board approval before starting treatment.

How does PlexusDx pricing compare, and do you work with Henry Meds or Reflexmd?

PlexusDx offers compounded semaglutide ($189/mo), oral semaglutide ($289/mo), and compounded tirzepatide ($289/mo) through licensed 503A pharmacies. We operate independently; our Precision Peptide Genetic Test ($298) can support your conversation with any provider, including those at Henry Meds or Reflexmd.

What should I know about side effects before choosing a platform?

GLP-1 side effects—nausea, vomiting, constipation, dehydration—occur in 30–50% of users and often improve with time or dose adjustment. Rare but serious risks include pancreatitis and gallbladder issues. Your medical history should guide which platform and medication are safest for you; discuss previous medication tolerability with your provider.

Can genetic testing help me choose between semaglutide and tirzepatide?

Your Precision Peptide Genetic Test results—particularly GIPR variants—may help provide context about your predispositions in peptide signaling.

Related Reading

• Henry Meds Cost
• Remedy Meds Cost
• Henry Meds Glp 1
• Henry Meds Tirzepatide

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.